As global pharmaceutical supply chains adjust to the latest wave of international tariffs, many manufacturers are reevaluating their reliance on offshore production. With increasing focus on supply stability, regulatory alignment, and long-term risk mitigation, Benuvia is seeing strong interest from international companies seeking U.S.-based manufacturing partners.

Based in Texas, Benuvia supports pharmaceutical and biotech companies with fully integrated API and drug product development and manufacturing. Our capabilities are built for agility, particularly in areas requiring complex chemistry, Schedule I–V controlled substances, and specialized dosage forms.

“Tariff pressures and supply disruptions have changed the conversation,” said Joe Giraudo, Director of Commercial Operations. “We’re hearing from partners in Europe, Asia, and Canada who are actively seeking US manufacturing partners. The priority is secure, scalable, U.S. compliant capacity that can support both clinical and commercial programs.”

Why Benuvia is Attracting Onshoring Interest:

• End-to-End Capabilities – API development and drug product manufacturing under one roof
• Regulatory Alignment – Deep expertise with FDA and DEA requirements
• Project Acceleration – CMC and regulatory support tailored for U.S. market entry
• Operational Flexibility – Ideal for dual-sourcing or full program relocation

Benuvia is currently working with several international partners to transition programs from overseas to our U.S. site, delivering both speed and regulatory clarity.

“There’s a strategic shift underway,” Giraudo added. “Manufacturers aren’t just reacting to global uncertainty, they’re building more resilient supply models. We’re ready to support that evolution with technical depth and a strong regulatory foundation.”

For those evaluating U.S. based CDMO partnerships, Benuvia’s team is available to discuss how we can support your development and manufacturing goals.